title: Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.
abstract: Castleman's disease represents an atypical lymphoproliferative disorder which is non-clonal but can turn malignant in the form of lymphoma, Kaposi's sarcoma or plasma cell dyscrasia. It has been reported in association with diseases like polyneuropathy organomegaly endocrinopathy monoclonal gammopathy skin changes syndrome and myeloma and very rarely it can be associated with cutaneous vasculitis as in our case. It relatively runs an aggressive course and has a shorter survival. No standard of care therapy is yet established for multicentric Castleman's disease accompanying myeloma. We successfully treated one such patient with bortezomib-based therapy.
authors.affiliation: Department of Haematology, Sir Ganga Ram Hospital, New Delhi, India. drafaqak@yahoo.co.in
authors.forename: Afaq Ahmad
authors.initials: AA
authors.lastname: Khan
authors.forename: Fouzia
authors.initials: F
authors.lastname: Siraj
authors.forename: Manorama
authors.initials: M
authors.lastname: Bhargava
authors.forename: Shyam
authors.initials: S
authors.lastname: Aggarwal
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005871:Castleman Disease / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib